Lilly could launch obesity drug in India next year, CEO says

Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/N6udhWA
via IFTTT